Sichuan Kelun Pharmaceutical Co Ltd (002422)

Currency in CNY
41.33
-2.11(-4.86%)
Closed·
Advertisement
002422 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
41.0044.40
52 wk Range
28.1452.78
Key Statistics
Bid/Ask
41.32 / 41.33
Prev. Close
43.44
Open
43.57
Day's Range
41-44.4
52 wk Range
28.14-52.78
Volume
30.59M
Average Volume (3m)
31.42M
1-Year Change
11.1918%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
002422 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
46.54
Upside
+12.60%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

8 Buy
0 Hold
1 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 46.54
(+12.60% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Buy47.00+13.72%-Upgrade20/04/2026
UBS
Hold40.00-3.22%46.00Downgrade29/09/2025
Goldman Sachs
Hold38.00-8.06%34.00Maintain29/08/2025

Sichuan Kelun Pharmaceutical Co Ltd Earnings Call Summary for H2/2025

  • Kelun-Biotech reported FY2025 revenue of CNY 2.06B, up 6.5% YoY, with gross margin improving 16.1% driven by higher-margin commercialized products.
  • Company posted net loss of CNY 380M (adjusted CNY 210M) as sales expenses surged 160% to CNY 475M amid aggressive commercialization push.
  • R&D expenditure increased 9.4% to CNY 1.32B, supporting pipeline of 30+ projects focused on oncology, immunology, and metabolic diseases.
  • Management forecasts FY2025-26 revenue at $2.57B-$2.89B with EPS of $0.13-$0.18, expecting continued growth from commercialization expansion.
  • Executives emphasized strong pipeline and financial stability despite near-term profitability pressures from elevated R&D and market expansion costs.
Last Updated: 02/04/2026, 19:36
Read Full Transcript

Earnings

Latest Release
29/04/2026
EPS / Forecast
0.30 / 0.40
Revenue / Forecast
4.26B / 4.89B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.99%
Dividend Yield
2.53%
Industry Median 1.79%
Annualised payout
1.10
Paid annually
5-Years Growth
+13.25%
Growth Streak

Compare 002422 to Peers and Sector

Metrics to compare
002422
Peers
Sector
Relationship
P/E Ratio
44.0x19.0x−0.4x
PEG Ratio
−1.150.380.00
Price/Book
2.8x2.3x2.6x
Price / LTM Sales
3.8x2.7x3.0x
Upside (Analyst Target)
10.0%33.5%56.0%
Fair Value Upside
Unlock19.9%9.1%Unlock

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.

Employees
20127
Market
China

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
358.08M22.51%15.56B
Other Institutional Investors
87.13M5.48%3.78B
Public Companies & Retail Investors
1.15B72.01%49.75B
Total
1.59B100.00%69.09B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Ya'an Development Investment Company Limited5.90%93,801,0744,074,719
Zhong Ou Fund Management Co., Ltd2.64%41,933,2581,821,581

People Also Watch

120.91
002409
-9.63%
30.47
002001
+1.53%
29.09
002558
-0.65%
40.34
002080
-6.49%

FAQ

What Is the Kelun Pharm A (Shenzhen: 002422) Share Price Today?

The Kelun Pharm A stock price today is 41.33 CNY.

What Stock Exchange Does Kelun Pharm A (002422) Trade On?

Kelun Pharm A is listed and trades on the Shenzhen Stock Exchange.

What Is the Ticker (Stock Symbol) for Kelun Pharm A?

The stock symbol (also called a 'ticker') for Kelun Pharm A is "002422."

Does Kelun Pharm A Pay Dividends? What’s The Current 002422 Dividend Yield?

Yes, 002422 Pays Dividends to its Shareholders. The current Kelun Pharm A dividend yield is 2.65%.

What Is the Current Kelun Pharm A Market Capitalisation?

As of today, Kelun Pharm A (Shenzhen: 002422) market cap is 65.73B CNY.

What Is Kelun Pharm A's (002422) Earnings Per Share (TTM)?

The Kelun Pharm A EPS is currently 0.99 (Trailing Twelve Months).

When Is the Next Kelun Pharm A Earnings Date?

Kelun Pharm A's next earnings report will be released on 27/08/2026.

Is 002422 a Buy or Sell From a Technical Analyst Perspective?

Based on today's Kelun Pharm A moving averages and other technical indicators, the daily buy/sell signal for 002422 stock is Strong Sell.

How Many Times Has Kelun Pharm A Stock Split?

Kelun Pharm A has split 3 times. (See the 002422 stock split history page for full effective split date and price information.)

How Many Employees Does Kelun Pharm A Have?

Kelun Pharm A has 20127 employees, based on their latest Companies House report.

What is the current trading status of Kelun Pharm A (Shenzhen: 002422)?

As of 03/08/2026, Kelun Pharm A (002422) is trading at a share price of 41.33 CNY, with a previous close of 43.44 CNY. The stock has fluctuated within a day range of 41.00 CNY to 44.40 CNY, while its 52-week range spans from 28.14 CNY to 52.78 CNY.

What Is Kelun Pharm A (002422) Price Target According to Analysts?

The average 12-month price target for Kelun Pharm A is 46.54 CNY, with a high estimate of 57 CNY and a low estimate of 29 CNY. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +12.60% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.